Literature DB >> 17869349

Antibodies against Epstein-Barr virus and herpesvirus type 6 are associated with the early phases of multiple sclerosis.

M Riverol, J Sepulcre, B Fernandez-Diez, P Villoslada, M Fernandez-Alonso, M Rubio, A Rodriguez, A Uccelli, L Brieva.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17869349     DOI： 10.1016/j.jneuroim.2007.08.010

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


× No keyword cloud information.
  7 in total

1.  Relation between Epstein-Barr virus and multiple sclerosis: analytic study of scientific production.

Authors:  O Santiago; J Gutierrez; A Sorlozano; J de Dios Luna; E Villegas; O Fernandez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-04-29       Impact factor: 3.267

2.  Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis.

Authors:  J W Lindsey; L M Hatfield; T Vu
Journal:  Eur J Neurol       Date:  2010-10       Impact factor: 6.089

Review 3.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 4.  Human Herpesviruses 6A and 6B in Brain Diseases: Association versus Causation.

Authors:  Anthony L Komaroff; Philip E Pellett; Steven Jacobson
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

Review 5.  Viruses and multiple sclerosis.

Authors:  Jussi Oskari Virtanen; Steve Jacobson
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-08       Impact factor: 4.388

Review 6.  CD4+ Cytotoxic T Cells Involved in the Development of EBV-Associated Diseases.

Authors:  Manuel Ruiz-Pablos
Journal:  Pathogens       Date:  2022-07-25

Review 7.  Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis.

Authors:  Yahya H Almohmeed; Alison Avenell; Lorna Aucott; Mark A Vickers
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.